I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Jessica Oien Biography and Net Worth

General Counsel of Cidara Therapeutics

Ms. Oien brings a breadth of legal experience to Cidara having served in senior legal roles across all aspects of biotech business, with significant expertise assisting companies emerging from clinical development to commercialization. Prior to joining Cidara, Ms. Oien served as Vice President, Compliance at Otonomy, Inc., where she developed and oversaw the commercial compliance program and was the legal lead for the commercial business. Ms. Oien served in similar roles as Vice President, Compliance for Pernix Therapeutics, Vice President, Legal Affairs & Compliance for Somaxon Pharmaceuticals, Inc., and Senior Director, Legal Affairs for Verus Pharmaceuticals. Ms. Oien provided legal consulting services for a robust clientele of early stage biotech companies providing legal support for numerous collaborations, and other research and development programs. Ms. Oien also served as Senior Director, Legal Affairs at Elan Corporation. Ms. Oien began her legal career as outside corporate counsel at national law firms including tenures at Brobeck, Phleger & Harrison and Milbank, Tweed, Hadley & McCloy. Ms. Oien received her J.D. from Loyola Law School and a B.A. in Economics and Political Science from North Dakota State University.

What is Jessica Oien's net worth?: The estimated net worth of Jessica Oien is at least $7,128.54 as of April 1st, 2021. Ms. Oien owns 307 shares of Cidara Therapeutics stock worth more than $7,129 as of December 22nd. This net worth evaluation does not reflect any other assets that Ms. Oien may own. Learn More about Jessica Oien's net worth.
How do I contact Jessica Oien?: The corporate mailing address for Ms. Oien and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Jessica Oien's contact information.
Has Jessica Oien been buying or selling shares of Cidara Therapeutics?: Jessica Oien has not been actively trading shares of Cidara Therapeutics during the past quarter. Most recently, Jessica Oien sold 58 shares of the business's stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $53.20, for a transaction totalling $3,085.60. Following the completion of the sale, the general counsel now directly owns 307 shares of the company's stock, valued at $16,332.40. Learn More on Jessica Oien's trading history.
Who are Cidara Therapeutics' active insiders?: Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.
Are insiders buying or selling shares of Cidara Therapeutics?: In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 8,000 shares worth more than $105,680.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 3,944 shares worth more than $51,223.36. The most recent insider tranaction occured on September, 11th when insider Taylor Sandison sold 924 shares worth more than $10,755.36. Insiders at Cidara Therapeutics own 7.6% of the company. Learn More about insider trades at Cidara Therapeutics.
Information on this page was last updated on 9/11/2024.

Jessica Oien Insider Trading History at Cidara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2021	Sell	58	$53.20	$3,085.60	307
1/5/2021	Sell	41	$41.20	$1,689.20	307
1/2/2020	Sell	41	$77.20	$3,165.20	348
9/27/2019	Sell	50	$37.20	$1,860.00	389

Jessica Oien Buying and Selling Activity at Cidara Therapeutics

Cidara Therapeutics Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Today's Range

Now: $23.22

$21.20

$24.00

50 Day Range

MA: $16.37

$10.17

$23.73

2 Week Range

Now: $23.22

$10.00

$24.99

Volume

148,362 shs

Average Volume

42,980 shs

Market Capitalization

$163.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

I was wrong. Dead wrong.

From Porter & Company | Ad